Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  GlaxoSmithKline Pharmaceuticals Limited    GLAXO   INE159A01016

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote National Stock Exchange O…
11/28/2016 11/29/2016 11/30/2016 12/01/2016 12/02/2016 Date
2728(c) 2684(c) 2720(c) 2750.05(c) 2710 Last
5 994 9 940 5 145 18 542 3 856 Volume
+1.56% -1.61% +1.34% +1.10% -1.46% Change
More quotes
Financials ( INR)
Sales 2017 30 602 M
EBIT 2017 5 133 M
Net income 2017 4 191 M
Finance 2017 8 029 M
Yield 2017 1,99%
Sales 2018 34 856 M
EBIT 2018 6 940 M
Net income 2018 5 401 M
Finance 2018 4 453 M
Yield 2018 2,13%
P/E ratio 2017 55,04
P/E ratio 2018 42,72
EV / Sales2017 7,27x
EV / Sales2018 6,49x
Capitalization 230 523 M
More Financials
Company
GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals.The company's product portfolio includes prescription medicines and vaccines.Its prescription medicines range across therapeutic areas such as anti-infective, dermatology,... 
Sector
Pharmaceuticals
Calendar
02/15Earnings Release
More about the company
Surperformance© ratings of GlaxoSmithKline Pharmaceut
Trading Rating : Investor Rating :
More Ratings
Latest news on GLAXOSMITHKLINE PHARMACEUT
12/02 TOP NEWS : Glaxo's Relvar Ellipta Approved For COPD In Japan
11/25 GLAXOSMITHKLINE PHARMACEUTICALS : partners with Habitat for Humanity India for a..
11/25 GLAXOSMITHKLINE : Files For EU Regulatory Approval For Shingles Vaccine
11/23 VECTURA : Revenue More Than Doubles Following Skyepharma Buy
11/23 TOP NEWS : GlaxoSmithKline's Mepolizumab Meets Phase 3 Trial Endpoints
11/22 HERE’S OUR TAKE ON THERAVANCE : TBPH) and GlaxoSmithKline plc (ADR) (NYSE..
11/21 TOP NEWS : Glaxo Submits US Regulatory Filing For COPD Treatment
11/18 GLAXOSMITHKLINE : ViiV Begins Two Phase III Studies For HIV-1
11/16 GLAXOSMITHKLINE : Sirukumab Studies Meet Primary Endpoints
11/16 GLAXOSMITHKLINE : Benlysta Shows Sustained Benefits In Long-Term Study
More news
Sector news : Pharmaceuticals - NEC
01:25aDJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Pharmaceuticals - NEC
Advertisement
Chart GLAXOSMITHKLINE PHARMACEUT
Duration : Period :
GlaxoSmithKline Pharmaceut Technical Analysis Chart | GLAXO | INE159A01016 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE P...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 2 792  INR
Spread / Average Target 2,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Deepak Shantilal Parekh Non-Executive Chairman
Andrew Aristidou Chief Financial Officer & Executive Director
Raju Krishnaswamy Executive Director & Technical Director
Vrishali Desai Vice President-Medical & Clinical Research
D. Sundaram Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PHARMA..-16.67%3 388
JOHNSON & JOHNSON9.00%304 591
PFIZER INC.-2.01%191 942
ROCHE HOLDING LTD.-19.61%188 878
NOVARTIS AG-19.07%178 737
MERCK & CO., INC.15.85%168 544
More Results